Regulator-monitor

Implement operational changes to assess and process consumer reports on side effects, ensuring additional resources are allocated for evaluations.

Sellers and distributors are mandated to cease the sale and distribution of the affected products immediately and comply with penalties for non-compliance, which may include fines up to RM50,000 or imprisonment.

Sellers must stop the sale and distribution of the canceled products immediately and monitor for compliance with NPRA regulations to avoid legal penalties.

Ensure that all labeling and safety information reflects the updated product name 'Prasugrel Viatris' instead of 'Prasugrel Mylan'.

The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.

Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.

Enhanced monitoring for products with hidden drug ingredients is required, leading to increased need for rapid reporting and investigation of adverse events associated with similar products.

Applicants must adhere to new timelines: submit a rapporteurs' allocation request 9 months prior to the intended MAA submission date, and submit their Letter of Intent at least 2 months before the MAA submission.

Stakeholders must express interest in the pilot by submitting an application form prior to the full submission of data, with the pilot set to run through 2027.

Manufacturers must now incorporate expert panel feedback into their conformity assessment processes, ensuring timely integration of provided expert advice into their evaluation and regulatory submissions.

Update local protocols to ensure parenteral nutrition is administered with filters in compliance with the new requirements.

Healthcare facilities must initiate the removal process for affected lots, isolate impacted products, and communicate the recall information to all relevant healthcare professionals. Compliance with the outlined return process is mandatory.

Pharmacies within healthcare establishments must review the safety information and adhere to the guidance issued by ANSM regarding the usage of the device.

Surgifrance must implement corrective actions, including the establishment of processes for handling complaints in 3 months, and a complaints register within 8 months.

Pharmacovigilance systems must be updated to monitor and report on the newly added medications.

Focus on therapeutic equivalence evaluations for generics

Affected healthcare facilities and distributors must immediately check their stock, remove BD ChloraPrep applicators from all kits, apply over-labels indicating the need for component removal, and notify any customers if they have transferred or resold these products.

Affected users must identify, segregate, and quarantine the kits, add warning labels, and ensure the removal of the recalled components prior to use.

Companies must ensure compliance with the Irish language requirements and complete mandatory OMS registration before regulatory submissions to prevent delays.

Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.

Developers of NAMs are encouraged to participate in early dialogues with EMA and are now able to submit NAM-derived data for independent evaluation under a voluntary data submission pilot.

Healthcare professionals should not initiate treatment with Avacopan Vifor for new patients and must review existing patients' treatment plans to ensure safe transitions to alternative therapies.

Manufacturers must familiarize themselves with the new procedure, including creating an EMA account and understanding the timelines for submitting the required briefing documents according to the established timetable for 2025 and 2026.

Companies preparing 510(k) submissions for dental composite resin devices must align with the recommendations specified in the new guidance, which include detailed testing and labeling criteria.

Manufacturers should align their premarket submissions for dental curing lights with the updated FDA guidance, ensuring to follow new recommendations on device description, performance testing, and labeling.

Ensure compliance with the updated reference list and adjust internal regulatory monitoring processes to align with the inclusion of new biologicals.

Increased vigilance and reporting obligations on illegal peptide products, with an emphasis on monitoring and managing safety signals pertaining to these substances.

Healthcare providers and distributors must immediately identify and quarantine affected products before destroying them after completing the recall actions. Compliance with FDA recall procedures is mandatory.

Review and update labeling processes in accordance with the newly published safety-related changes for affected products.

MAHs must allocate resources to develop and maintain SPPs, ensuring they meet the new regulatory requirements and are ready for submission within two days upon request in crisis situations.

Implementation of new dosing schedules and an emphasis on monitoring for potential adverse reactions as outlined in the prescribing information.

Regulatory compliance processes may need updates to incorporate the new recombinant endotoxins testing method and guidelines established under the ICMRA framework.

AZRL LTD must proceed with the recall of FastPen 40mg from all locations and suspend marketing activities until compliance is verified.

Healthcare facilities must complete preoperative checks, manage emergency O2 flow during usage, and return the response form to GE Healthcare within a maximum of 30 days.

All users of the affected analyzers are required to reply to the notification letter within 10 days and implement increased monitoring of device performance to prevent liquid leaks.

Laboratories must immediately quarantine and return the affected product, and communicate with patients to manage their follow-up testing appropriately.

Patients will be treated with an initial dose of 19 mg of Mimrylo, administered weekly, with careful monitoring to maintain hematocrit levels below 45%. The operation of post-marketing surveillance will be affected due to the introduction of this new drug.

Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.

Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.

Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

The marketing authorization holder must submit amended product information reflecting the new safety guidelines by October 9, 2026, with translations due by August 10, 2026.

Update labeling to reflect the new indication for Stelara, and ensure compliance with associated regulatory activities including safety monitoring.

Labeling and risk management updates are required to reflect the new drug approval, including the incorporation of safety and efficacy data from the VERIFY trial.

Customers are required to quarantine affected kits, complete response forms, and destroy the kits. Notification must also be sent to distributors who should inform their customers of these updated actions.

Health care professionals must complete and return the enclosed Reply Verification Tracking Form (RVTF) indicating the quantities of affected units to return, and monitor patients following the standard of care while discontinuing the use of these catheters.

Regulatory teams must update product labeling to reflect the new indication and assess signal management considerations for capivasertib.

Implement enhanced surveillance and tracking of Salmonella cases linked to imported eggs, potentially increasing ICSR submissions related to these infections.

Parents are encouraged to ensure their children receive timely vaccinations according to the NHS schedule to increase overall immunization rates and adherence to WHO guidelines.

Compounding pharmacies must verify that all components used in injectable drugs are suitable for their intended use and discontinue the use of any glutathione labeled for dietary supplement purposes, particularly if sourced from Medisca.

Update product labeling to include Lisraya as the first oral treatment for dermatomyositis, ensuring that all marketing and educational materials reflect its approval and associated safety information.

Review and update internal compliance and reporting workflows to align with the FDA's reporting requirements for the latest oncology product approvals.

Cattle producers must administer Bimectin injection within specified timelines (24 hours post-birth, at castration, or on wound appearance) and observe a 35-day withdrawal period before slaughter to prevent drug residues in food.

All impacted products must be identified, segregated, and quarantined. Users are required to add appropriate warning labels and must exercise extreme caution if using the Manifolds is unavoidable.

Customers must immediately identify and quarantine all unused affected devices (Bravo CF capsule delivery devices, product numbers FGS-0635 and FGS-0636) and return them to Medtronic for replacement.

Veterinary practitioners must now adjust their prescribing practices in accordance with the AMEG guidelines and monitor compliance with the new restrictions as outlined in the EMA's directive.

Comments on the draft guidance must be submitted by November 27, 2026. Facilities must comply with CGMP in accordance with specified enforcement policies to avoid potential enforcement actions.

Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.

Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.

Health professionals and stakeholders should review the safety signals linked to CAROTONE products in their signal management processes.

Marketing authorization holders (MAHs) must review and potentially update their product labeling to align with the new regulations by 11 April 2029 for products authorized before 11 May 2024.

Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.

Healthcare organizations should review the NPRA annual report to ensure compliance with updated safety monitoring practices and adjust their reporting and signal management processes accordingly.

Regulatory requirements for daratumumab will need to be reviewed in light of the orphan designation status granted by the EMA.

Healthcare providers must implement a follow-up process for patients with identified cobalt-chrome modular neck components, monitoring for new or unexpected symptoms including pain, stiffness, or instability.

Regulatory Intelligence teams must monitor updates regarding the ongoing CHMP evaluation and potential implications for existing marketing authorizations.

Update all internal and external communications, labels, and marketing materials to reflect the new product name, Svariya, instead of Rivaroxaban Koanaa.

Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.

Healthcare professionals must include daraxonrasib in adverse event reporting as the new treatment option is now available for eligible patients.

Affected healthcare facilities should remove all Automated Impella Controllers from use and stock, ensure annual preventive maintenance is followed, and report any adverse reactions to Abiomed or MedWatch.

Facilities using these devices must immediately cease their use, segregate them from other stock, and return them to Boston Scientific. Relevant personnel must be notified of this recall.

Organisations should review their DBS checking arrangements, especially prioritizing checks that include the Children's Barred List for those working with children, as part of their compliance with the new definition from September 2026.

Submit bluetongue samples to APHA with forms attached securely on the outside of the parcel to facilitate rapid booking into their digital sample handling system.

Monitor and reassess affected pain and arthritis products, ensuring compliance with safety reporting protocols for products listed with known hidden ingredients.

Consumers should consult healthcare professionals if using this product and report any adverse effects to FDA’s MedWatch Safety Information.

Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.

Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.

Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.

Regulatory intelligence teams must update workflows to exclude clove oil as an anesthetic for fish and ensure compliance with the guidance, including awareness of approved alternatives.

Ensure compliance checks are reinforced in the inspection readiness processes to account for potential non-compliance surrounding product imports.

Ongoing investigations into unlawful vaping products are expected to result in further enforcement actions, including additional seizures and potential penalties for non-compliance with the Therapeutic Goods Act.

Regulatory intelligence workflows should address this enforcement action as part of ongoing compliance monitoring regarding the sale and promotion of unapproved therapeutic goods.

Organizations must enhance signal management processes to track and report adverse events related to Melanotan II products, ensuring compliance with safety regulations.

Companies must implement a strategy to upgrade from Windows 10 to Windows 11 and ensure compliance with essential safety principles, including notifying customers about potential vulnerabilities.

Entities affected by this notification must review their plasma product lot processes and ensure compliance with NPRA regulations. Affected stakeholders should adjust workflows to address non-compliance issues.

Implement an immediate review of affected vaccine lots and ensure all relevant stakeholders are informed of the compliance issues for Signal Management processes.

Organizations must increase scrutiny and evaluation of vaccine safety profiles for lots identified in the notification of non-compliance.

Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.

Stakeholders can submit NAMs data by completing the prescribed application form, available until Q3 2027.

Organizations involved in medical device compliance should prepare for potential future changes requiring MHRA-issued licenses for devices entering the market.

Pharmaceutical companies should prepare to assess the impact of hepatic impairment early in drug development, particularly for drugs that require pharmacokinetic assessments.

Update internal systems and workflows to integrate monthly Excel reports from EMA starting March 2025, ensuring timely capture of information on medicines under evaluation and any extension applications.

Regulatory Intelligence leads should initiate monitoring of feedback and prepare for potential regulatory adjustments related to the specified substances.

Small business dispensers are encouraged to complete a mandatory assessment survey by September 22, 2026, and do not need to submit information to the FDA while utilizing these exemptions.

Stakeholders are advised to submit comments on the draft guidance by 11/18/2026, using docket number FDA-2026-D-8561 to ensure FDA considers their feedback before finalizing the document.